文献速递胸部肿瘤

肿瘤突变负荷作为可切除非小细胞肺癌的生物标志物

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2018-08-14

LACE-Bio-II研究对908例可切除早期NSCLC肿瘤标本用1538基因靶向 panel 测序,评估TMB等标志物的预后与预测价值。高非同义TMB(>8突变/Mb)与较好预后相关;低非同义TMB(≤4突变/Mb)患者辅助化疗的LCSS获益更明显。DNA修复通路突变、TILs、TP53亚型及瘤内异质性均无预后或预测意义。

要点

  • 高非同义TMB(>8突变/Mb)与可切除NSCLC较好OS、DFS和LCSS相关。
  • 低非同义TMB(≤4突变/Mb)患者辅助化疗的LCSS获益更明显。
  • DNA修复通路突变、TILs、TP53亚型及瘤内异质性无预后或预测意义。

核心结论

  • 高非同义TMB与可切除NSCLC较好预后相关。
  • 低非同义TMB患者辅助化疗的LCSS获益更明显。

研究设计与样本

  • LACE-Bio-II研究对908例可切除NSCLC的FFPE肿瘤标本用1538基因靶向 panel 测序。
  • 标本来自辅助治疗 landmark 临床试验中前瞻性治疗的患者,采用严格过滤排除胚系变异和福尔马林固定相关假象。
  • 采用按试验分层的Cox模型分析DFS、OS和LCSS,并调整治疗、年龄、性别、体能评分、组织学、手术方式和分期。

主要发现

  • 908例肿瘤样本中鉴定出1515个基因的非同义突变。
  • 高非同义TMB(>8突变/Mb)对OS、DFS和LCSS均为预后良好因素。
  • 低非同义TMB(≤4突变/Mb)患者辅助化疗的LCSS获益更明显。
  • DNA修复通路突变、肿瘤浸润淋巴细胞、TP53改变亚型和瘤内异质性既无预后也无预测意义。
  • 因高错误发现率,单个基因突变的显著效应难以确定。

关键数值与推荐

  • 高非同义TMB定义为>8突变/Mb,与较好OS、DFS和LCSS相关。
  • 低非同义TMB定义为≤4突变/Mb,该组辅助化疗的LCSS获益更明显。

临床怎么用

  • 对可切除NSCLC检测非同义TMB有助于预后分层。
  • 低非同义TMB(≤4突变/Mb)患者辅助化疗的LCSS获益更明显,可辅助治疗决策。
  • DNA修复通路突变、TILs、TP53亚型及瘤内异质性目前不宜用于预后或预测。

局限性

  • 单个基因突变的显著效应因高错误发现率难以确定。
  • 研究结果为回顾性分析,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non-small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically useful tests. We report findings from the Lung Adjuvant Cisplatin Evaluation (LACE)-Bio-II study, in which we analyzed next-generation sequencing and long-term outcomes data from > 900 patients with early-stage NSCLC treated prospectively in adjuvant landmark clinical trials. We used a targeted gene panel to assess the prognostic and predictive effect of mutations in individual genes, DNA repair pathways, and tumor mutation burden (TMB). METHODS: A total of 908 unmatched, formalin-fixed, paraffin-embedded, resected lung cancer tumor specimens were sequenced using a targeted panel of 1,538 genes. Stringent filtering criteria were applied to exclude germline variants and artifacts related to formalin fixation. Disease-free survival, overall survival, and lung cancer-specific survival (LCSS) were assessed in Cox models stratified by trial and adjusted for treatment, age, sex, performance score, histology, type of surgery, and stage. RESULTS: Nonsynonymous mutations were identified in 1,515 genes in 908 tumor samples. High nonsynonymous TMB (> 8 mutations/Mb) was prognostic for favorable outcomes (ie, overall survival, disease-free survival, and LCSS) in patients with resected NSCLC. LCSS benefit with adjuvant chemotherapy was more pronounced in patients with low nonsynonymous TMBs (≤ 4 mutations/Mb). Presence of mutations in DNA repair pathways, tumor-infiltrating lymphocytes, TP53 alteration subtype, and intratumor heterogeneity was neither prognostic nor predictive. Statistically significant effect of mutations in individual genes was difficult to determine due to high false-discovery rates. CONCLUSION: High nonsynonymous TMB was associated with a better prognosis in patients with resected NSCLC. In addition, the benefit of adjuvant chemotherapy on LCSS was more pronounced in patients with low nonsynonymous TMBs. Studies are warranted to confirm these findings.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Devarakonda S, Rotolo F, Tsao MS, et al. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 30106638. doi:10.1200/JCO.2018.78.1963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。